Výsledky vyhledávání - "Brooke Geibel"

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults

Autor: Joan Gu, Manisha Madhoo, Matthew Dauphin, Olga Brawman-Mintzer, Roger S. McIntyre, Rajnish Mago, Dan V. Iosifescu, Brooke Geibel, Elias Sarkis, Cynthia Richards, Richard H. Weisler

Publikováno v: Journal of Clinical Psychopharmacology

Supplemental digital content is available in the text.
Purpose/Background Psychostimulant augmentation is considered a potential treatment strategy for individuals with major depressive disorder who do not adequately respond to antidepressant mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f40348d4095c16035829e998aeea495
http://europepmc.org/articles/PMC6039401

Zobrazit plný text záznamu

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy

Autor: Matthew Dauphin, Rajnish Mago, James M. Reynolds, Elias Sarkis, Cynthia Richards, Brooke Geibel, Dan V. Iosifescu

Publikováno v: Journal of Psychopharmacology (Oxford, England)

Background: This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d845c8f46206f9edbcd64be5befc56cd
http://europepmc.org/articles/PMC5606302

Zobrazit plný text záznamu

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment

Autor: Brooke Geibel, Tim Henkel, William K. Smith, Thomas Marbury, Cynthia Richards, Paul C. McGovern, James A. Dowell

Publikováno v: Open Forum Infectious Diseases

Background Taniborbactam is a novel, non-ß-lactam, ß-lactamase inhibitor with activity against serine (Class A, C, D) and metallo (Class B) ß-lactamases including epidemiologically important carbapenemases. Both cefepime and taniborbactam are pred

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6dd3599b1ca62ad7b1cb05c865c231d
http://europepmc.org/articles/PMC7777653

Zobrazit plný text záznamu

1401. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects

Autor: Daniel Dickerson, Timothy Henkel, Brooke Geibel, James A. Dowell

Publikováno v: Open Forum Infectious Diseases

Background VNRX-5133 is a novel, non-β-lactam, β-lactamase inhibitor with potent and selective direct inhibitory activity against serine- and metallo-β-lactamases. VNRX-5133, combined with the β-lactam antibiotic cefepime, is being developed for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::befcd2ec077d92f206ee0c10f75046f3
https://doi.org/10.1093/ofid/ofy210.1232

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání